VU 0155041 sodium salt

• CAT Number: I010738
• CAS Number: 1259372-69-4
• Molecular Formula: C14H14Cl2NNaO3
• Molecular Weight: 338.16
• Purity: ≥95%
• Synonyms: cis-2-[[(3,5-Dichlorophenyl)amino]carbonyl]cyclohexanecarboxylic acid sodium salt
• Target: Neuronal Signaling
• Solubility: Soluble to 25 mM in water
• Storage: Desiccate at RT
• IUPAC Name: sodium;(1R,2S)-2-[(3,5-dichlorophenyl)carbamoyl]cyclohexane-1-carboxylate
• InChI: InChI=1S/C14H15Cl2NO3.Na/c15-8-5-9(16)7-10(6-8)17-13(18)11-3-1-2-4-12(11)14(19)20;/h5-7,11-12H,1-4H2,(H,17,18)(H,19,20);/q;+1/p-1/t11-,12+;/m0./s1
• InChIKey: ZFDOLOCYGVTGDQ-ZVWHLABXSA-M
• SMILES: C1CC[C@H]([C@H](C1)C(=O)NC2=CC(=CC(=C2)Cl)Cl)C(=O)[O-].[Na+]

VU 0155041 sodium salt（Cat No.:I010738）is a selective, small molecule inhibitor that targets the G protein-coupled receptor 40 (GPR40), which is involved in regulating insulin secretion in response to fatty acids. It has shown potential in improving glucose homeostasis and insulin sensitivity, making it a candidate for treating type 2 diabetes and metabolic disorders. Preclinical studies suggest that VU 0155041 sodium salt enhances glucose-induced insulin secretion without causing hypoglycemia. Ongoing research is focused on evaluating its safety, efficacy, and long-term benefits in managing diabetes and other related conditions.